The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern California
• Collaborators: Hebrew SeniorLife; National Institute on Aging (NIA)
• Treatments: Angiotensin Receptor Antagonists; Antihypertensive Agents; Candesartan; Candesartan cilexetil; Hydrochlorothiazide; Lisinopril; Metoprolol; Nifedipine

Criteria

Inclusion Criteria:

• 60 years or older

• Hypertension

• Cognitive criteria: score either 10 or less out of 15 for the executive clock draw test 1 (CLOX1) or less than or equal to 1 standard deviation from the corresponding age specific mean on the immediate memory subtest

Exclusion Criteria:

• Intolerance to ACEI or ARB

• History of congestive heart failure

• History of diabetes mellitus

• History of stroke (less than 6 months)